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Latest publication:
• Stability of lysozyme in aqueous extremolyte solutions during heat 
shock and accelerated thermal conditions. Plos One Journal, 
January 2014, Volume 9, Issue 1, e86244
• The formation of oxytocin dimers is suppressed by the zinc-
aspartate-oxytocin complex. J. Pharm. Sci., 2013, DOI 
10.1002/jps.23546 (early published online)
• Aspartate buffer and divalent metal ions affect oxytocin in 




























































































Sandostatin®		 Novartis Liquid	inj. 3		yr,	2-8°C 4.2
Vasopressins	and	analogs
Desmopressin	 DDAVP® Ferring Liquid	inj. 4	yr,	2-8°C 4-5
Octostim® Ferring Liquid	inj. 4	yr,	2-8°C 4
Minrin® Ferring Liquid	inj. 4	yr,	2-8°C 4
Felypressin Citanest	3%	
Octapressin®
Densply Liquid	inj. 3	yr,	15-25°C 3.5-
5.2













Oxytocin Syntocinon® Defiante Liquid	inj. 4	yr,	2-8°C 4
Carbetocin Pabal® Ferring Liquid	inj. 2	yr,		2-8°C 3.8
Oxytocin	antagonist
Atosiban Tractocile® Ferring Liquid	inj. 4yr,	2-8°C 4.5


















































Novartis Liquid		inj. 5	yr,		2-8°C 3-5
Human	parathyroid	hormone	[hPTH	(1–34)]
Teriparatide	 Forsteo® Eli	Lily Liquid	inj. 2	yr,		2-8°C
Fusion	inhibitor	of	HIV-1	with	CD4	cells



































most peptide drugs have to be stored 


























































Table 2 Degradation pathways and possible stabilization strategies for peptides 
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Table 2 Degradation pathways and possible stabilization strategies for peptides 
including amino acid residues involved in the degradation, continued
Conclusion
• In aqueous solutions peptides are often unstable. 
• Peptides have unique structures that the side chain 
of nearly all of the amino acid residues are fully 
solvent exposed, allowing maximal contact with 
solvents 
• the degradation rates appear to correlate with the 
degree of solvent exposure. 
• Based on knowledge of the peptide’s structure and 
an understanding of the predominant degradation 
pathways, the strategies may be developed to 
achieve adequate stability of the formulation. 
• The degradation pathways of peptides are 
mainly dependent on the amino acid sequence. 
• The most prominent degradation pathways for 
peptides are hydrolysis, oxidation, and 
dimerization. 
• Formulating peptides in a specific pH with a 
specific buffer, avoiding oxygen reactive species, 
and minimizing solvent exposure eliminate 
chemical degradation. 
• Increasing solution viscosity by using sugars or 
polymers reduces peptide mobility and further 
decelerates physical degradation. 
Conclusion
Instability	is	the	most	stable	
characteristic	of	
a	dissolved	peptide
Christina	Avanti,	2011
Instabilities	are	a	natural	way	to	
achieve	thermodynamic	equilibrium
Christina	Avanti,	2012

